Valuation: Nanobiotix

Market Cap 1.7B 1.94B 1.57B 1.44B 2.73B 187B 2.77B 18.73B 7.36B 91.4B 7.29B 7.13B 316B P/E 2026 *
-81.5x
P/E 2027 * -141x
Enterprise Value 1.74B 2B 1.61B 1.48B 2.8B 192B 2.85B 19.23B 7.56B 93.88B 7.49B 7.33B 324B EV / Sales 2026 *
39.8x
EV / Sales 2027 * 32.5x
Free-Float
88.26%
Yield 2026 *
-
Yield 2027 * -
1 day-3.68%
1 week-1.82%
Current month+4.30%
1 month+10.50%
3 months+20.17%
6 months+81.17%
Current year+71.69%
1 week 32.7
Extreme 32.7
37.46
1 month 28.94
Extreme 28.94
37.46
Current year 16.66
Extreme 16.66
47.66
1 year 4.15
Extreme 4.15
47.66
3 years 2.62
Extreme 2.62
47.66
5 years 1.61
Extreme 1.612
47.66
10 years 1.61
Extreme 1.612
47.66
Manager TitleAgeSince
Chief Executive Officer 55 2009-11-15
Director of Finance/CFO 54 2021-05-31
Chief Tech/Sci/R&D Officer 68 2023-09-04
Director TitleAgeSince
Director/Board Member 76 2011-06-22
Director/Board Member 65 2013-12-31
Director/Board Member 57 2014-06-17
Date Insider Type Main position Quantity % Market Cap.
2/20/26 Buy

Chairman

1,100 0.0023%
2/13/26 Buy

Chairman

1,500 0.0031%
12/3/25 Sell

Chief Executive Officer

295,000 0.6153%
Change 5-day change 1-year change 3-year change Capi.($)
-3.68%-1.82%+632.60%+484.29% 2.02B
-1.07%-1.27%+0.95%+5.66% 50.35B
-2.85%-6.25%+366.61%+572.09% 39.21B
+1.98%+4.82%+13.71%+61.68% 34.6B
+1.78%+0.73%+32.68%-4.80% 34.52B
+0.06%+1.56%+4.41%+27.42% 27.05B
-3.27%-5.67% - - 16.68B
+1.64%+0.45%+70.86%+121.18% 15.11B
+0.29%+1.02%+14.95%+17.80% 13.85B
-1.21%+0.73%+18.02%-30.96% 13.18B
Average -0.63%-0.07%+128.31%+139.37% 24.66B
Weighted average by Cap. -0.34%+0.39%+82.37%+122.12%

Financials

2026 *2027 *
Net sales 43.85M 50.17M 40.56M 37.21M 70.43M 4.83B 71.66M 484M 190M 2.36B 188M 184M 8.15B 54.52M 62.38M 50.42M 46.27M 87.57M 6.01B 89.09M 601M 236M 2.94B 234M 229M 10.13B
Net income -7.65M -8.75M -7.07M -6.49M -12.28M -843M -12.49M -84.32M -33.12M -412M -32.85M -32.12M -1.42B 6.46M 7.4M 5.98M 5.49M 10.38M 713M 10.56M 71.3M 28.01M 348M 27.77M 27.16M 1.2B
Net Debt 46M 52.62M 42.54M 39.04M 73.88M 5.07B 75.16M 507M 199M 2.48B 198M 193M 8.55B 76.4M 87.41M 70.66M 64.84M 123M 8.42B 125M 843M 331M 4.11B 328M 321M 14.2B
Logo Nanobiotix
Nanobiotix is a pioneer and leader in nanomedicine that has developed a revolutionary approach to the treatment of cancer. The company focuses its effort on the development of its products portfolio entirely patented, NanoXray, innovation based on the physical mode of action of nanoparticles that, under the action of radiation, allow maximizing the absorption of X-rays inside the cancer cells without increasing the dose received by the surrounding healthy tissue. NanoXray products are compatible with standard radiotherapy treatments and are intended to potentially treat a wide variety of cancers via multiple routes of administration. The company's resources are primarily devoted to the development of its lead product candidate: JNJ-1900 (NBTXR3), which is the product of its proprietary oncology platform and has already achieved market authorization in Europe for the treatment of patients with soft tissue sarcoma under.
Employees
100
Date Price Change Volume
26-07-16 €33.48 -3.68% 120,384
26-07-15 €34.76 -3.98% 147,588
26-07-14 €36.20 +3.61% 141,510
26-07-13 €34.94 -1.74% 101,870
26-07-10 €35.56 +4.28% 196,106
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
33.48EUR
Average target price
52.20EUR
Spread / Average Target
+55.91%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. NANO Stock